Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
67 Metformin Trials Near You
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerMetformin + Esomeprazole for Pre-eclampsia
Newark, Delaware
This trial tested a slow-releasing form of the medication metformin on pregnant women with early pre-eclampsia. The goal was to see if it could help prolong their pregnancies. The treatment works by lowering harmful substances that can cause blood vessel problems. Results showed that metformin could indeed help extend pregnancy duration in these women. Metformin has been studied for its potential to reduce the risk of pre-eclampsia and has shown promise in both preclinical and clinical studies.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:18 - 55
Sex:Female
Key Eligibility Criteria
Disqualifiers:Diabetes, Metabolic Acidosis, Others
Must Not Be Taking:Metformin, Esomeprazole, Glyburide, Others
38 Participants Needed
Personalized Diabetes Medication Adjustment for Type 2 Diabetes
Decatur, Georgia
Diabetes is a disorder of high blood glucose, that tends to get worse; over time, patients need more and more drugs. This pattern is caused by overwork of the body's insulin-producing β-cells, because patients' glucose levels are typically above normal; if the investigators kept glucose levels normal - reducing β-cell work - the investigators might be able to keep the disease from getting worse. This trial is aimed to show that adjusting the drugs to keep glucose levels normal, can help to preserve β-cell function compared to usual diabetes care, possibly reduce the tendency to develop the eye and kidney complications of diabetes, and might also be more cost-effective than usual care.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:40 - 75
Key Eligibility Criteria
Disqualifiers:CVD, Heart Failure, Pregnancy, Others
Must Not Be Taking:Systemic Glucocorticoids
127 Participants Needed
Everolimus + Letrozole + Metformin for Endometrial Cancer
Voorhees Township, New Jersey
The goal of this clinical research study is to learn if the combination of everolimus, letrozole, and metformin can help to control recurrent or progressive endometrial cancer. The safety of this drug combination will also be studied.
Everolimus is designed to block a protein inside cancer cells that is involved in cancer growth.
Letrozole is designed to block a protein from making estrogen. This may interfere with the growth of cancer cells.
Metformin is commonly used to control blood sugar levels in patients with diabetes. It is designed to lower insulin levels, which may slow or stop the growth of endometrial cancer cells.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Uterine Sarcomas, Brain Metastases, Cardiac Disease, Others
Must Not Be Taking:Corticosteroids, Immunosuppressants, MTOR Inhibitors, Others
62 Participants Needed
Why Other Patients Applied
I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me.
AG
Paralysis PatientAge: 50
My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort.
HZ
Arthritis PatientAge: 78
I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials.
WR
Obesity PatientAge: 58
As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money.
IZ
Healthy Volunteer PatientAge: 38
I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new.
FF
ADHD PatientAge: 31
Metformin for Prediabetes
Iowa City, Iowa
The goal of this clinical trial is to investigate whether metformin improves vascular function in individuals with prediabetes. The main questions it aims to answer are:
1. Does metformin improve large conduit artery endothelial function in individuals with prediabetes?
2. Does metformin improve microvascular endothelial function in individuals with prediabetes?
Researchers will compare metformin to a placebo to see if metformin improves vascular function in prediabetes.
The trial duration is 12 weeks. Participants will take metformin or a placebo once a day for 2 weeks. After 2 weeks, participants will take metformin or a placebo twice a day for the remaining 10 weeks. There will be a screening visit, two baseline visits, a 4-week safety visit, and two 12-week end-of-study visits. Adherence will be calculated from pill count and adverse events will be quantified via a questionnaire.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 55
Key Eligibility Criteria
Disqualifiers:Smoking, Hypertension, Diabetes, Others
Must Not Be Taking:Metformin, Vitamin C, Others
30 Participants Needed
Metformin XR for Preventing Multiple Myeloma
Londonderry, New Hampshire
The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) from developing multiple myeloma.
The names of the study drug involved in this study is:
* Metformin, extended release
* Placebo ( a pill that has no active ingredients)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:High-risk Smoldering Myeloma, Other Malignancy, Pregnancy, Renal Or Liver Failure, Others
Must Not Be Taking:Diabetes Medications, Investigational Agents
60 Participants Needed
Metformin for FSGS
New York, New York
The primary objective of this study is to determine whether extended-release MF (in addition to standard of care (S-o-C)) is superior to placebo in reducing podocyte injury and promoting podocyte survival by 6-months in Focal Segmental Glomerulosclerosis (FSGS).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Liver Disease, Diabetes, Dementia, Others
Must Be Taking:Glucocorticoids
30 Participants Needed
Paxalisib + Metformin + Ketogenic Diet for Glioblastoma
New York, New York
This trial is for patients with new or recurring aggressive brain cancer called glioblastoma. They will take two drugs regularly and follow a high-fat, low-carb diet. The treatment aims to block cancer growth signals and reduce the energy supply to cancer cells.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Type 1 Diabetes, QT Interval ≥ 450 Msec, Ongoing Malignancy, Others
Must Be Taking:Paxalisib, Metformin
33 Participants Needed
Ketogenic Diet + Metformin for Glioblastoma
New York, New York
This trial is for men and women with aggressive brain tumors. It uses a high-fat, low-carb diet and a diabetes medication to lower blood sugar levels. The goal is to see if this approach can help slow down tumor growth. The high-fat, low-carb diet is being explored as an additional treatment for brain tumors, with some studies suggesting it may help control tumor growth and improve response to standard treatments.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Diabetes, Other Malignancy, Alcoholism, Others
Must Be Taking:Metformin
36 Participants Needed
Metformin for Immune Dysregulation in Drug Users
Birmingham, Alabama
This randomized clinical trial (RCT) evaluates whether metformin can reduce systemic inflammation and improve immune function in individuals with a history of injection drug use, with or without HIV. Participants will receive metformin or placebo and undergo immune system assessments, including vaccine response evaluations.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 64
Key Eligibility Criteria
Disqualifiers:Diabetes, Renal Impairment, Liver Disease, Others
Must Not Be Taking:Metformin, Diabetes Medications, Furosemide, Others
100 Participants Needed
Digital + Metformin for Prediabetes
Memphis, Tennessee
This is a first-in survivor, single-arm pilot study with the goal of establishing evidence of feasibility and safety of a combined pharmacologic (metformin) and lifestyle intervention (using an existing digital platform) to prevent diabetes in prediabetic adult survivors of childhood cancer.
Primary Objective
The primary aim of this proposal is to establish the feasibility and safety of a 24-week combined metformin + intensive lifestyle intervention among adult survivors with prediabetes (including a 12-week lifestyle alone run-in followed by 12-week combined intervention among survivors remaining prediabetic).
Primary endpoints of this trial will be adherence to 1) daily metformin administration and 2) completion of required core-curriculum of the lifestyle change intervention. Safety will be assessed using the Global Rating of Side Effects Burden
Secondary Objectives
The secondary aim is to assess preliminary evidence for efficacy of the combined metformin + intensive lifestyle intervention on glycemic control and insulin resistance. Glycemic control will be measured by fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) and insulin resistance measured by the homeostatic model assessment (HOMA-IR) and IGF- binding protein 1 (IGF-BP1; a measure of insulin sensitivity strongly correlated with euglycemic insulin clamp testing).
Exploratory Objectives
To assess preliminary evidence for efficacy of the combined metformin + intensive lifestyle intervention on weight, other anthropometric measures, blood pressure and lipid profile, physical activity (self-reported and as measured by accelerometer), frailty measures, and health-related quality of life (HRQOL). We will also assess diabetes development at future SJLIFE visits.
To assess measures of participation in the lifestyle change program as well as barriers to participation and medication adherence.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 44
Key Eligibility Criteria
Disqualifiers:Diabetes, Kidney Disease, Cardiovascular, Others
Must Be Taking:Metformin
100 Participants Needed
Valsartan + Celecoxib + Metformin for Type 2 Diabetes
Albany, New York
Evaluation of safety, tolerability and superiority of RK-01, a valsartan plus celecoxib dual add-on to metformin-HCL XR over metformin in newly diagnosed and obese adult type 2 diabetes patients with high blood pressure, arthritis and inadequate glycemic control with metformin monotherapy, diet and exercise over 26 weeks of treatment.
Objective: To assess effect of RK-01 on HbA1c levels, beta cell function and insulin resistance with co-administration of valsartan, celecoxib and metformin-HCl XR relative to metformin monotherapy.
Hypothesis: After 26 weeks of treatment with valsartan, celecoxib and metformin-HCl XR provides greater improvements in glycemic, inflammatory and atherogenic parameters compared to metformin monotherapy.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Type 1 Diabetes, Cardiovascular Diseases, Renal Disease, Liver Disease, Others
Must Be Taking:Metformin
115 Participants Needed
Metformin and Remote Monitoring for Brain Cancer
Rochester, Minnesota
This phase III trial evaluates whether patient care can be done remotely for patients having cranial (skull) radiation or who have previously had cranial radiation. In addition, this trial compares study outcomes between patients who get metformin and those who do not. Cranial radiation, an essential component of brain tumor treatment, can result in significant negative effects on cognitive (the ability to clearly think, learn, and remember) function. Wearable devices have been used in the field of neurology for seizure detection and assessment of patients with movement disorders. Wearable device technology has also been implemented for remote monitoring of cancer patients and for cancer clinical trials. Metformin is the active ingredient in a drug used to treat type 2 diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. Use of metformin may reduce risk of cognitive decline following radiation therapy within the skull (intracranial). These effects may be further strengthen by addition of device-based physical activity promotion. Mayo Test Drive is a web-based platform for remote self-administered cognitive assessment. Using Mayo Test Drive may help determine whether patient care can be done remotely, while simultaneously evaluating benefits of health promotion through use of a wearable watch device and metformin in preventing radiation-related cognitive decline.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Nursing, Imprisonment, Others
Must Not Be Taking:Metformin, Resveratrol, CoQ10, Others
100 Participants Needed
Metformin and Standard Therapy for Glioblastoma
Montréal, Quebec
This trial tests if Metformin, a diabetes drug, can improve treatment for patients with newly diagnosed aggressive brain cancer (GBM). Metformin, a commonly used drug for the treatment of diabetes, has recently emerged as a promising anticancer molecule. It may help by slowing cancer cell growth and enhancing current treatments.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Diabetes, Prior Malignancy, Severe Comorbidity, Others
Must Be Taking:Temozolomide, Metformin
50 Participants Needed
Metformin for Fragile X Syndrome
Montreal, Quebec
This trial tests metformin in people with fragile X syndrome aged 6 to 35 years. Metformin, a diabetes medication, may help improve their behavior, language skills, and control their appetite by balancing brain signals. The study will assess its safety and effectiveness over several months. Metformin, commonly used for diabetes, has shown promise in improving cognitive and behavioral issues in fragile X syndrome based on preliminary studies.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:6 - 35
Key Eligibility Criteria
Disqualifiers:Non-cooperative, Major Illness, Metabolic Acidosis, Others
Must Not Be Taking:Metformin
120 Participants Needed
Abemaciclib + Letrozole +/- Metformin for Endometrial Cancer
Boston, Massachusetts
This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer and low-grade serous ovarian cancer.
The drugs involved in this study are:
* Abemaciclib (also known as Verzenio™)
* Letrozole (also known as Femara®)
* Metformin (also known as Glucophage®)
* Zotatifin (also known as eFT226)
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Sex:Female
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Cardiovascular Risk, Others
Must Not Be Taking:Metformin, CDK4/6 Inhibitors
130 Participants Needed
Metformin for Infant Brain Injury
Boston, Massachusetts
Infants with hypoxic-ischemic encephalopathy (HIE) are at high risk for neurodevelopmental impairment, despite current standards of care. Adjunctive treatments to promote brain repair are needed. The antidiabetic drug metformin has recently been recognized as a neurorestorative agent, but, to date, has not been used in infants. Herein, the investigator describes a clinical trial with the aim of demonstrating the safety and feasibility of metformin use to improve neurodevelopmental outcomes in infants with HIE.
Stay on current meds
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:3 - 6
Key Eligibility Criteria
Disqualifiers:Genetic Disorders, Liver Disease, Others
Must Not Be Taking:Antidiabetics, Steroids, Diuretics, Others
30 Participants Needed
Metformin + Glipizide for Diabetes
Boston, Massachusetts
The SUGAR-MGH investigators are studying the influence of inherited gene variants on the response to two commonly prescribed type 2 diabetes medications, metformin and glipizide. They hypothesize that variants in genes that are associated with type 2 diabetes or related traits may impact the effect of anti-diabetic medications. In addition, physiological responses to an insulin secretagogue or an insulin sensitizer may shed light on the mechanism of action of reported genetic associations.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Pregnancy, Liver Disease, Kidney Disease, CAD, Others
Must Not Be Taking:Diabetes Meds, Glucocorticoids
1033 Participants Needed
Metformin Response During Meal Test for Type 2 Diabetes
Boston, Massachusetts
The purpose of this research study is to examine whether specific genes (e.g. SLC16A11) affect how human beings respond to food and a medication that is commonly used to treat type 2 diabetes. The food the investigators will be studying is specially prepared to contain protein, carbohydrate, and fat. The drug the investigators are studying is metformin. The investigators hypothesize that physiological responses to the meal and to the medication will differ between carriers and non-carriers of genes associated with type 2 diabetes.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Liver Disease, Renal Impairment, Others
Must Not Be Taking:Diabetes Medications, Glucocorticoids
1017 Participants Needed
Metformin for ALS
Gainesville, Florida
This trial is testing if Metformin, a diabetes drug, is safe and effective for patients with C9orf72 ALS. The drug aims to block harmful proteins linked to their genetic mutation. Metformin has been used to treat type 2 diabetes for more than 60 years and is currently being investigated for its potential anticancer effects.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Renal Disease, Liver Disease, Cancer, Others
Must Be Taking:Metformin
18 Participants Needed
HPV Vaccine + Imiquimod + Metformin for Cervical Cancer
Houston, Texas
The goal of this clinical trial is to explore whether additional treatments can help strengthen the participant's immune system to fight cancer caused by the Human Papillomavirus (HPV), a virus spread through intimate skin-to-skin contact. The trial will also monitor the safety of these treatments. The main questions it aims to answer are:
Does the combination of treatments help the participant's body fight the cancer more effectively when used alongside standard therapy? What side effects or medical issues arise when using these experimental treatments? Researchers will use three experimental therapies along with the participant's standard treatment to find out if these therapies work better together than standard treatment alone.
Participants will:
Receive HPV vaccinations during the 2nd and 4th week of radiation, and again at weeks 8, 10, 12, and 16 after completing radiation.
Have blood samples taken, tumor cells brushed from the surface, and imiquimod cream applied during each visit.
Take a daily metformin pill and apply an imiquimod suppository three times a week for two weeks after each visit.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 64
Sex:Female
Key Eligibility Criteria
Disqualifiers:Untreated Brain Metastases, Allergic Reactions, Uncontrolled Illness, Others
Must Be Taking:HPV Vaccines, Metformin
85 Participants Needed
Treatments for Prediabetes and Obesity
San Antonio, Texas
The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight. The investigators also want to reduce participants risk of heart problems. The study team will look at how these treatments affect metabolism and other body functions to help find new ways to treat diabetes and obesity in the future.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Type 2 Diabetes, Major Oncologic, Others
Must Not Be Taking:Selected Therapies
64 Participants Needed
Diabetes Medications for Prediabetes
San Antonio, Texas
HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Diabetes, Heart Failure, Cancer, Others
Must Be Taking:Metformin, Pioglitazone
700 Participants Needed
Multiple Interventions for Menopause
Aurora, Colorado
What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? The ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and increase productivity.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2, 3
Age:45 - 55
Sex:Female
Key Eligibility Criteria
Disqualifiers:Pregnancy, Untreated Alcoholism, Abnormal Bleeding, Others
200 Participants Needed
Metformin is used widely in the treatment of type 2 diabetes. It has off-label indications for use in the prevention of diabetes and in hyperinsulinar obesity. In medical practices, the implementation of metformin for these off-label indications is variable, often at the level of the provider. Multiple retrospective investigations have also shown a clinical benefit in men with prostate cancer who are incidentally treated with metformin.
This pragmatic study will test the feasibility of enrolling patients who have glucose intolerance (as defined by HbA1c of 5.7-6.4%) and/or who have increased BMI (BMI greater than or equal to 25 kg/m2) to a randomized pragmatic study of metformin plus lifestyle modification information versus lifestyle modification information only. For purposes of the scope of this project and the study's feasibility, this will be implemented in a group of prostate cancer patients, who may have additional benefits from metformin.
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Sex:Male
Key Eligibility Criteria
Disqualifiers:Diabetes Therapy, Liver Disease, Others
Must Not Be Taking:Antidiabetics, Carbonic Anhydrase Inhibitors
100 Participants Needed
Metformin for Muscle Health in Older Adults
Salt Lake City, Utah
Muscle atrophy and insulin resistance are common after bed rest in healthy older adults. Metformin treatment has been shown to improve insulin sensitivity and attenuate muscle loss in insulin resistance adults though the mechanisms are not fully known. Metformin used as a preventive strategy to maintain muscle and metabolic health in bed ridden older adults has not been investigated.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Early Phase 1
Age:60+
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Diabetes, Cancer, Others
Must Not Be Taking:Anticoagulants, Corticosteroids, Estrogen
64 Participants Needed
Metformin for Fibromyalgia
Salt Lake City, Utah
The main purpose of the project is to evaluate the safety and efficacy of low dose metformin for improving symptoms associated with fibromyalgia syndrome (FMS) via modulating neuroinflammatory pathways. The investigators hypothesize that FMS patients in the low-dose metformin conditions will show greater improvement in FMS symptoms than those who are in the placebo group. Further, the investigators hypothesize that metformin will increase phosphorylated AMPK in peripheral immune cells of FMS patients and will decrease the transcription of mTORC1, NLRP3 inflammasome, and nociceptive cytokines interleukin 1beta and interleukin 18.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Diabetes, Pregnancy, Cardiovascular, Autoimmune, Others
Must Not Be Taking:Weight Controlling Medications
72 Participants Needed
Metformin for Muscle Weakness
Salt Lake City, Utah
A hallmark of aging is an impaired ability to adequately recover following a stressor, such as muscle disuse, resulting in muscle fibrosis and weakness thereby increasing the risk for falls and loss of independence. Mechanistic-based therapeutic strategies to enhance muscle recovery in older adults do not exist. Metformin has been implicated to have positive effects on muscle size and function through non-glycemic mechanisms. Metformin has been shown to enhance macrophage function and lessen cellular senescence burden by targeting SASP in a variety of muscle interstitial cells. However, the role of metformin to improve muscle recovery in older adults following disuse atrophy through immunomodulating and senomorphic mechanisms have not been examined. Therefore, the purpose of this study is to conduct a randomized, double blind, placebo-controlled clinical trial in older adult participants to determine if short-term metformin delivery (vs placebo) during the recovery phase following disuse atrophy can improve muscle regrowth.
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:60+
Key Eligibility Criteria
Disqualifiers:Cardiovascular, Endocrine, Kidney, Vascular, Cancer, Others
Must Not Be Taking:Anticoagulants, Corticosteroids, Androgens, Estrogens
50 Participants Needed
This is a 12-month, single center, three-arm parallel design, double-blind, randomized clinical trial, to compare the effects of supplemental dietary fiber and metformin (MET) alone and in combination over 12 months on glucose metabolism (insulin resistance \[IR\]), inflammation and BMI in adolescents with obesity and IR, and to assess the relationship between therapeutic intervention(s) and changes in gut microbiome composition and function.
Since MET and FIBER have been shown to reduce weight and increase insulin sensitivity through distinct but overlapping mechanisms of action, our central hypothesis is that the combination of FIBER + MET will have a synergistic effect and be more effective than FIBER or MET alone in improving metabolic function (IR) and reducing BMI and inflammation in adolescents with obesity, IR and family history (FM) of T2DM.
.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:12 - 18
Key Eligibility Criteria
Disqualifiers:T2DM, Hypertension, Chronic Disease, Others
Must Not Be Taking:Insulin, Antibiotics, Probiotics, Others
90 Participants Needed
Combination Drugs for Drug Interactions
Spokane, Washington
The objective of this study is to confirm the feasibility of using a panel of endogenous substrates/metabolites as a robust biomarker of OCTs and OATs by conducting a controlled, comprehensive clinical drug-drug interaction study in healthy adult volunteers. Metformin and furosemide will be used as probe drugs for OCTs and OATs, respectively; cimetidine and probenecid will be used as corresponding inhibitors. Results from this study will validate this novel approach, which will be extended to children by collaborators at Children's Mercy Hospital in Kansas City, MO.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Chronic Illness, Tobacco, Cannabis, Others
Must Not Be Taking:Prescription Drugs, Supplements
32 Participants Needed
Metformin for Insulin Resistance in Breast Cancer
Riverside, California
This phase III trial evaluates how often women develop insulin resistance and type-2 diabetes and compares metformin with usual care to usual care alone in treating insulin resistance in women with stage I-III breast cancer after chemotherapy. Insulin resistance occurs when cells stop responding to insulin and is a risk factor for developing diabetes and heart disease. Higher levels of insulin have been shown to be associated with aggressive breast cancer. Metformin hydrochloride decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body's use of the glucose. Metformin as well as standard of care diet and exercise education is known to lower blood sugar. However, chemotherapy may accelerate metabolic disorders, such as high blood sugar, and the impact of metformin in these breast cancer survivors is not known. Giving metformin with usual care may be more effective than usual care alone in preventing or reversing insulin resistance in women with stage I-III breast cancer after chemotherapy.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Sex:Female
Key Eligibility Criteria
Disqualifiers:Diabetes, Renal Insufficiency, Pregnancy, Others
Must Not Be Taking:Oral Antidiabetics, Tamoxifen
200 Participants Needed
Know someone looking for new options?
Spread the word
Learn More About Power
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Bask GillCEO at Power
Frequently Asked Questions
How much do clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.How do clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length is 12 months.How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.Do I need to be insured to participate in a medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.What are the newest clinical trials ?
Most recently, we added Valsartan + Celecoxib + Metformin for Type 2 Diabetes, Multiple Interventions for Menopause and Metformin for Infant Brain Injury to the Power online platform.Popular Searches
By Condition
By Location
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.